Ruth B Etzioni

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi The case for early detection
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, USA
    Nat Rev Cancer 3:243-52. 2003
  2. ncbi Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden
    Ruth Etzioni
    Program in Biostatistics, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Clin Cancer Res 18:6742-7. 2012
  3. ncbi The prostate cancer conundrum revisited : Treatment changes and prostate cancer mortality declines
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
    Cancer 118:5955-63. 2012
  4. ncbi Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality
    R Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 91:1033-9. 1999
  5. ncbi Analyzing patterns of staining in immunohistochemical studies: application to a study of prostate cancer recurrence
    Ruth Etzioni
    Translational and Outcomes Research, Fred Hutchinson Cancer Research Center, Mailstop M2 B230, 1100 Fairview Avenue North, P O Box 19024, Seattle, WA 98109, USA
    Cancer Epidemiol Biomarkers Prev 14:1040-6. 2005
  6. ncbi Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
    Ruth Etzioni
    Program in Biostatistics, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2 B230, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 13:1640-5. 2004
  7. ncbi Quantifying the role of PSA screening in the US prostate cancer mortality decline
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Causes Control 19:175-81. 2008
  8. ncbi Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach
    Ruth Etzioni
    Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Med Decis Making 28:323-31. 2008
  9. ncbi Combining biomarkers to detect disease with application to prostate cancer
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA, USA
    Biostatistics 4:523-38. 2003
  10. ncbi Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial
    Ruth D Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Urol 174:877-81. 2005

Detail Information

Publications42

  1. ncbi The case for early detection
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, USA
    Nat Rev Cancer 3:243-52. 2003
    ..been revitalized by the advent of novel molecular technologies that can identify cellular changes at the level of the genome or proteome, but how can we harness these new technologies to develop effective and practical screening tests?..
  2. ncbi Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden
    Ruth Etzioni
    Program in Biostatistics, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Clin Cancer Res 18:6742-7. 2012
    ..The extent to which this increase reflects treatment of nonlethal disease detected through prostate-specific antigen (PSA) screening is unknown...
  3. ncbi The prostate cancer conundrum revisited : Treatment changes and prostate cancer mortality declines
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
    Cancer 118:5955-63. 2012
    ..Prostate cancer mortality rates in the United States declined by >40% between 1991 and 2005. The impact of changes in primary treatment and adjuvant and neoadjuvant hormone therapy on this decline is unknown...
  4. ncbi Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality
    R Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 91:1033-9. 1999
    ....
  5. ncbi Analyzing patterns of staining in immunohistochemical studies: application to a study of prostate cancer recurrence
    Ruth Etzioni
    Translational and Outcomes Research, Fred Hutchinson Cancer Research Center, Mailstop M2 B230, 1100 Fairview Avenue North, P O Box 19024, Seattle, WA 98109, USA
    Cancer Epidemiol Biomarkers Prev 14:1040-6. 2005
    ..In this article, we introduce analytic approaches that explicitly consider both the frequency and intensity of tissue staining...
  6. ncbi Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
    Ruth Etzioni
    Program in Biostatistics, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2 B230, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 13:1640-5. 2004
    ..The combined use of free and total prostate-specific antigen (PSA) in early detection of prostate cancer has been controversial. This article systematically evaluates the discriminating capacity of a large number of combination tests...
  7. ncbi Quantifying the role of PSA screening in the US prostate cancer mortality decline
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Causes Control 19:175-81. 2008
    ..To quantify the plausible contribution of prostate-specific antigen (PSA) screening to the nearly 30% decline in the US prostate cancer mortality rate observed during the 1990s...
  8. ncbi Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach
    Ruth Etzioni
    Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Med Decis Making 28:323-31. 2008
    ..The objective was to quantify this link between PSA screening and the decline in distant stage incidence...
  9. ncbi Combining biomarkers to detect disease with application to prostate cancer
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA, USA
    Biostatistics 4:523-38. 2003
    ..The methods are applied to data on free and total PSA levels among prostate cancer cases and matched controls enrolled in the Physicians' Health Study...
  10. ncbi Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial
    Ruth D Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Urol 174:877-81. 2005
    ..We estimated the long-term effects of finasteride on PSA in men with and without a prostate cancer diagnosis at the end of the study...
  11. ncbi Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence
    Ruth D Etzioni
    Translational and Outcomes Research Group, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, M2 B230, PO Box 19024, Seattle, WA 98109, USA
    J Natl Cancer Inst 99:1510-5. 2007
    ..We therefore recommend that other methods be explored to incorporate information about PSA kinetics that could ultimately improve--and even transform--how we detect and treat prostate cancer...
  12. ncbi Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends
    Ruth Etzioni
    Program in Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 94:981-90. 2002
    ..Overdiagnosis was defined as the detection of prostate cancer through PSA testing that otherwise would not have been diagnosed within the patient's lifetime...
  13. ncbi Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends
    Donatello Telesca
    Department of Statistics, University of Washington, Seattle, WA 98195 4322, USA
    Biometrics 64:10-9. 2008
    ....
  14. ncbi Measuring costs: administrative claims data, clinical trials, and beyond
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Med Care 40:III63-72. 2002
    ..Several of these approaches are nonparametric and therefore may be expected to be robust against the non-standard features that are often encountered when analyzing medical cost data...
  15. ncbi Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer
    Scott D Ramsey
    Department of Medicine, University of Washington, Seattle, USA
    Am J Gastroenterol 97:440-5. 2002
    ..CONCLUSIONS: Cancer-attributable medical costs can be substantial for long term survivors, and exceed expected costs of surveillance. Future research is need to determine the components of excess cost in this survivor group...
  16. ncbi Calibrating disease progression models using population data: a critical precursor to policy development in cancer control
    Roman Gulati
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biostatistics 11:707-19. 2010
    ..The model produces representative outcomes for selected PSA screening policies and is shown to be useful for informing the development of sound cancer control policy...
  17. ncbi Statistical issues in the evaluation of screening and early detection modalities
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Urol Oncol 26:308-15. 2008
    ..I review several observational studies of PSA benefit and discuss the use of computer models for inferring the impact of screening from trends in population mortality...
  18. ncbi Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer
    Scott D Ramsey
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer 109:2222-8. 2007
    ..The population included Medicare patients (age >or=65 years) who were diagnosed with local or regional stage colorectal cancer between 1986 and 1996...
  19. ncbi Trends in treatment costs for localized prostate cancer: the healthy screenee effect
    Steven B Zeliadt
    Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Med Care 45:154-9. 2007
    ..We sought to obtain estimates of trends in initial treatment costs during the prostate-specific antigen (PSA) era that account for the changing patient case-mix associated with screening...
  20. ncbi Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer
    Steven B Zeliadt
    Fred Hutchinson Cancer Research Center, Health Services Department, University of Washington School of Public Health and Community Medicine, Seattle, WA 98109 1024, USA
    Int J Radiat Oncol Biol Phys 66:395-402. 2006
    ..This study examines the effectiveness of adjuvant ADT combined with radiotherapy for a wide range of patients treated in the 1990s...
  21. ncbi Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase
    Alan R Kristal
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Cancer 106:320-8. 2006
    ..The objective of this study was to examine whether demographic and lifestyle characteristics are associated with prostate-specific antigen (PSA) levels and the rate of PSA increase (PSA velocity)...
  22. ncbi What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 20:740-50. 2011
    ....
  23. ncbi Androgen receptor polymorphisms and the incidence of prostate cancer
    Chu Chen
    Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 11:1033-40. 2002
    ..32-0.98), compared with men with > or =22 CAG repeats and >17 GGC repeats. Our results do not support the hypothesis that a small number of CAG or GGC repeats in the androgen receptor gene increases a man's risk of prostate cancer...
  24. ncbi Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema
    Scott D Ramsey
    Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, WA 98109, USA
    N Engl J Med 348:2092-102. 2003
    ..The National Emphysema Treatment Trial, a randomized clinical trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, included a prospective economic analysis...
  25. ncbi Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial
    Chu Chen
    Program in Epidemiology, Fred Hutchinson Cancer Research Center, and Department of Epidemiology, University of Washington, Seattle, 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 12:1410-6. 2003
    ..The suggestions that intraprostatic androgen activity may increase risk and that serum estrogens may decrease risk, warrant additional study...
  26. ncbi Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
    Urology 59:251-5. 2002
    ..Should PSA screening prove efficacious, efforts to promote regular use among both black and white men will likely be needed...
  27. ncbi Case-control studies of the efficacy of cancer screening: overcoming bias from nonrandom patterns of screening
    Noel S Weiss
    University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington 98195 7236, USA
    Epidemiology 15:409-13. 2004
    ..We describe circumstances in which confounding from these sources can be dealt with satisfactorily by means of restriction or adjustment, and other circumstances in which it cannot...
  28. ncbi Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999
    Steven B Zeliadt
    Department of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Urology 64:1171-6. 2004
    ..To assess trends in the initial care of nonmetastatic prostate cancer, including the use of primary and adjuvant androgen deprivation therapy (ADT), using population-based treatment claims from 1991 to 1999...
  29. ncbi An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States
    Pamela A Shaw
    Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA
    Am J Epidemiol 160:1059-69. 2004
    ..Ecologic analyses of the effectiveness of PSA testing should be interpreted with caution...
  30. ncbi Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States
    Megan Dann Fesinmeyer
    Fred Hutchinson Cancer Research Center, Department of Veterans Affairs Puget Sound Health Care System, Fairview Avenue North, M2 B230, PO Box 19024, Seattle WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 18:808-15. 2009
    ..0% (under different survival for obese and nonobese cases) in 2002. We conclude that increasing obesity prevalence since 1980 has partially obscured declines in prostate cancer mortality...
  31. ncbi Combining results of microarray experiments: a rank aggregation approach
    Robert P DeConde
    Public Health Science Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Stat Appl Genet Mol Biol 5:Article15. 2006
    ..We apply all three algorithms to aggregate the results of five microarray studies of prostate cancer...
  32. ncbi Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer
    Najib Lamharzi
    Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Int J Cancer 105:480-3. 2003
    ....
  33. ncbi IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer
    Danielle M Friedrichsen
    Division of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Prostate 65:44-51. 2005
    ..Several polymorphisms within the IGF-I and IGFBP-3 coding regions have been associated with increased serum protein levels...
  34. ncbi Combining longitudinal studies of PSA
    Lurdes Y T Inoue
    University of Washington, Department of Biostatistics, F 600 Health Sciences Building, Campus Mail Stop 357232, Seattle, WA 98195, USA
    Biostatistics 5:483-500. 2004
    ....
  35. ncbi Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease
    Vincent S Fan
    Health Services Research and Development Center of Excellence, Veterans Affairs Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108 1597, USA
    Arch Intern Med 167:2345-53. 2007
    ....
  36. ncbi Metastases of prostate cancer express estrogen receptor-beta
    Janice S Lai
    Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Urology 64:814-20. 2004
    ..05) was detected. CONCLUSIONS: Our data have shown that ERbeta is expressed in CaP metastases, validating the initiation of studies to evaluate selective ER modulators for treatment of advanced CaP...
  37. ncbi Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer
    Scott D Ramsey
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington, Seattle, USA
    Gastroenterology 125:1645-50. 2003
    ..01). CONCLUSIONS: Colorectal cancer screening can substantially reduce prediagnosis evaluation costs. These savings are of interest to health plans and should be factored into cost-effectiveness evaluations of screening programs...
  38. ncbi Cluster-based network model for time-course gene expression data
    Lurdes Y T Inoue
    Department of Biostatistics, University of Washington, F 600 Health Sciences Building, Campus Mail Stop 357232, Seattle, WA 98195, USA
    Biostatistics 8:507-25. 2007
    ..The latter application shows that with a combined statistical/bioinformatics analyses, we are able to extract gene-to-gene relationships supported by the literature as well as new plausible relationships...
  39. ncbi Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma
    Stacy Moore
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Int J Cancer 114:563-71. 2005
    ..These results indicate that loss of SCD expression is a frequent event in prostate adenocarcinoma, and further supports a role for altered lipid metabolism as a factor in the process of carcinogenesis...
  40. ncbi Modelling the effect of screening for cervical cancer on the population
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 364:224-6. 2004
  41. ncbi Costs of pulmonary rehabilitation and predictors of adherence in the National Emphysema Treatment Trial
    Vincent S Fan
    VA Puget Sound Health Care System, Health Services Research and Development Center of Excellence, Seattle, WA, USA
    COPD 5:105-16. 2008
    ..A better understanding of patient factors such as socioeconomic status, depression, anxiety and transportation issues may improve adherence to pulmonary rehabilitation...
  42. ncbi Prostate cancer early detection. Clinical practice guidelines in oncology
    Mark H Kawachi
    J Natl Compr Canc Netw 5:714-36. 2007

Research Grants8

  1. Primary Prevention Versus Screening for Prostate Cancer
    Ruth Etzioni; Fiscal Year: 2005
    ..The final model will be made available to investigators through a dedicated website which will allow users to run the model with their own settings for key cost and efficacy parameters. ..
  2. Modeling US Prostate Cancer Trends: PSA, Treatment & Ra*
    Ruth Etzioni; Fiscal Year: 2007
    ....
  3. Outcomes Based Guideline Development for Prostate Cancer Screening and Treatment
    Ruth D Etzioni; Fiscal Year: 2010
    ..The proposed research aims to improve how these guidelines are produced by providing policy makers with a computerized decision support tool that will quantify the benefit-harm tradeoffs associated with candidate guidelines. ..